Tobacco, Nicotine, and E-Cigarettes Research Report

  1. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
  2. Agaku IT, King BA, Husten CG, et al. Tobacco product use among adults—United States, 2012-2013. MMWR Morb Mortal Wkly Rep. 2014;63(25):542-547.
  3. Stanton CA, Keith DR, Gaalema DE, et al. Trends in tobacco use among US adults with chronic health conditions: National Survey on Drug Use and Health 2005-2013. Prev Med. 2016;92:160-168. doi:10.1016/j.ypmed.2016.04.008.
  4. Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the U.S. population. Tob Control. 2014;23(e2):e147-e153. doi:10.1136/tobaccocontrol-2013-051466.
  5. Kollins SH, Adcock RA. ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: implications for smoking and nicotine dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2014;52:70-78. doi:10.1016/j.pnpbp.2014.02.002.
  6. Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA. 2014;311(2):172-182. doi:10.1001/jama.2013.284985.
  7. Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville (MD): SAMHSA; 2017. Accessed September 14, 2017.
  8. National Center for Health Statistics. National Health Interview Survey, 1997-2016. Centers for Disease Control and Prevention; 2017. Accessed September 14, 2017.
  9. Substance Abuse and Mental Health Services Administration. Adults with Mental Illness of Substance Use Disorder Account for 40 Percent of All Cigarettes Smoked. Rockville, MD: SAMHSA; 2013. Accessed October 6, 2017.
  10. Jamal A, Homa DM, O’Connor E, et al. Current cigarette smoking among adults - United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2015;64(44):1233-1240. doi:10.15585/mmwr.mm6444a2.
  11. Roberts ME, Doogan NJ, Kurti AN, et al. Rural tobacco use across the United States: How rural and urban areas differ, broken down by census regions and divisions. Health Place. 2016;39:153-159. doi:10.1016/j.healthplace.2016.04.001.
  12. Miech, R. A., Johnston, L. D., Patrick, M. E., O’Malley, P. M., Bachman, J. G., & Schulenberg J. E. (2023). Monitoring the Future National Survey Results on Drug Use, 1975-2022. Monitoring the Future Monograph Series. Ann Arbor: Institute for Social Research, The University of Michigan.
  13. Singh T, Arrazola RA, Corey CG, et al. Tobacco Use Among Middle and High School Students--United States, 2011-2015. MMWR Morb Mortal Wkly Rep. 2016;65(14):361-367. doi:10.15585/mmwr.mm6514a1.
  14. Warner KE. Frequency of E-Cigarette Use and Cigarette Smoking by American Students in 2014. Am J Prev Med. 2016;51(2):179-184. doi:10.1016/j.amepre.2015.12.004.
  15. Mantey DS, Cooper MR, Clendennen SL, Pasch KE, Perry CL. E-Cigarette Marketing Exposure Is Associated With E-Cigarette Use Among US Youth. J Adolesc Health Off Publ Soc Adolesc Med. 2016;58(6):686-690. doi:10.1016/j.jadohealth.2016.03.003.
  16. Gilreath TD, Leventhal A, Barrington-Trimis JL, et al. Patterns of Alternative Tobacco Product Use: Emergence of Hookah and E-cigarettes as Preferred Products Amongst Youth. J Adolesc Health Off Publ Soc Adolesc Med. 2016;58(2):181-185. doi:10.1016/j.jadohealth.2015.10.001.
  17. Arrazola RA, Singh T, Corey CG, et al. Tobacco use among middle and high school students - United States, 2011-2014. MMWR Morb Mortal Wkly Rep. 2015;64(14):381-385.
  18. Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA. 2014;311(2):164-171. doi:10.1001/jama.2013.285112.
  19. Maciosek MV, Xu X, Butani AL, Pechacek TF. Smoking-attributable medical expenditures by age, sex, and smoking status estimated using a relative risk approach. Prev Med. 2015;77:162-167. doi:10.1016/j.ypmed.2015.05.019.
  20. Picciotto MR, Mineur YS. Molecules and circuits involved in nicotine addiction: The many faces of smoking. Neuropharmacology. 2014;76 Pt B:545-553. doi:10.1016/j.neuropharm.2013.04.028.
  21. Balfour DJK. The role of mesoaccumbens dopamine in nicotine dependence. Curr Top Behav Neurosci. 2015;24:55-98. doi:10.1007/978-3-319-13482-6_3.
  22. National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine. Reducing Tobacco-Related Cancer Incidence and Mortality: Workshop Summary. Washington (DC): National Academies Press (US); 2013.
  23. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health. 1997;50(4):307-364. doi:10.1080/009841097160393.
  24. Hukkanen J, Jacob P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115. doi:10.1124/pr.57.1.3.
  25. Centers for Disease Control and Prevention (CDC). Quitting smoking among adults—United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513-1519.
  26. National Cancer Institute. Cigarette Smoking: Health Risks and How to Quit. National Cancer Institute. Published 2016. Accessed September 14, 2017.
  27. Cosgrove KP, Esterlis I, Sandiego C, Petrulli R, Morris ED. Imaging Tobacco Smoking with PET and SPECT. Curr Top Behav Neurosci. 2015;24:1-17. doi:10.1007/978-3-319-13482-6_1.
  28. Brody AL, Mukhin AG, Mamoun MS, et al. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. JAMA Psychiatry. 2014;71(7):797-805. doi:10.1001/jamapsychiatry.2014.138.
  29. Claus ED, Blaine SK, Filbey FM, Mayer AR, Hutchison KE. Association between nicotine dependence severity, BOLD response to smoking cues, and functional connectivity. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(12):2363-2372. doi:10.1038/npp.2013.134.
  30. Jackson KJ, Muldoon PP, De Biasi M, Damaj MI. New mechanisms and perspectives in nicotine withdrawal. Neuropharmacology. 2015;96(Pt B):223-234. doi:10.1016/j.neuropharm.2014.11.009.
  31. McLaughlin I, Dani JA, De Biasi M. Nicotine withdrawal. Curr Top Behav Neurosci. 2015;24:99-123. doi:10.1007/978-3-319-13482-6_4.
  32. Anstey KJ, von Sanden C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007;166(4):367-378. doi:10.1093/aje/kwm116.
  33. Ashare RL, Falcone M, Lerman C. Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment. Neuropharmacology. 2014;76 Pt B:581-591. doi:10.1016/j.neuropharm.2013.04.034.
  34. Jasinska AJ, Zorick T, Brody AL, Stein EA. Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans. Neuropharmacology. 2014;84:111-122. doi:10.1016/j.neuropharm.2013.02.015.
  35. Jaehne A, Unbehaun T, Feige B, et al. Sleep changes in smokers before, during and 3 months after nicotine withdrawal. Addict Biol. 2015;20(4):747-755. doi:10.1111/adb.12151.
  36. Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C, Rose JE. Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2001;3(2):101-109. doi:10.1080/14622200110042000.
  37. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146. doi:10.1002/14651858.CD000146.pub4.
  38. Carpenter MJ, Jardin BF, Burris JL, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs. 2013;73(5):407-426. doi:10.1007/s40265-013-0038-y.
  39. Schnoll RA, Goelz PM, Veluz-Wilkins A, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med. 2015;175(4):504-511. doi:10.1001/jamainternmed.2014.8313.
  40. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10:CD008286. doi:10.1002/14651858.CD008286.pub2.
  41. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016;3:CD008286. doi:10.1002/14651858.CD008286.pub3.
  42. Hogg RC. Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2016;18(5):509-523. doi:10.1093/ntr/ntv245.
  43. Hoffman AC, Evans SE. Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2013;15(3):622-632. doi:10.1093/ntr/nts192.
  44. National Cancer Institute. SEER Stat Fact Sheets: Cancer of Any Site.
  45. Müezzinler A, Mons U, Gellert C, et al. Smoking and All-cause Mortality in Older Adults: Results From the CHANCES Consortium. Am J Prev Med. 2015;49(5):e53-e63. doi:10.1016/j.amepre.2015.04.004.
  46. Goldman DP, Zheng Y, Girosi F, et al. The benefits of risk factor prevention in Americans aged 51 years and older. Am J Public Health. 2009;99(11):2096-2101. doi:10.2105/AJPH.2009.172627.
  47. Centers for Disease Control and Prevention. What Are the Risk Factors for Lung Cancer? Published May 31, 2017. Accessed December 1, 2017.
  48. Schwartz AG, Cote ML. Epidemiology of Lung Cancer. Adv Exp Med Biol. 2016;893:21-41. doi:10.1007/978-3-319-24223-1_2.
  49. Lee PN. Epidemiological evidence relating snus to health—an updated review based on recent publications. Harm Reduct J. 2013;10:36. doi:10.1186/1477-7517-10-36.
  50. Zuo L, He F, Sergakis GG, et al. Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. Am J Physiol Lung Cell Mol Physiol. 2014;307(3):L205-L218. doi:10.1152/ajplung.00330.2013.
  51. Kelishadi R, Poursafa P. A review on the genetic, environmental, and lifestyle aspects of the early-life origins of cardiovascular disease. Curr Probl Pediatr Adolesc Health Care. 2014;44(3):54-72. doi:10.1016/j.cppeds.2013.12.005.
  52. Morris PB, Ference BA, Jahangir E, et al. Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes: Clinical Perspectives From the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol. 2015;66(12):1378-1391. doi:10.1016/j.jacc.2015.07.037.
  53. Athyros VG, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin. 2013;29(10):1263-1274. doi:10.1185/03007995.2013.827566.
  54. Tian J, Venn AJ, Blizzard L, Patton GC, Dwyer T, Gall SL. Smoking status and health-related quality of life: a longitudinal study in young adults. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2016;25(3):669-685. doi:10.1007/s11136-015-1112-6.
  55. Jacobs M, Alonso AM, Sherin KM, et al. Policies to restrict secondhand smoke exposure: American College of Preventive Medicine Position Statement. Am J Prev Med. 2013;45(3):360-367. doi:10.1016/j.amepre.2013.05.007.
  56. Al-Sayed EM, Ibrahim KS. Second-hand tobacco smoke and children. Toxicol Ind Health. 2014;30(7):635-644. doi:10.1177/0748233712462473.
  57. Martins-Green M, Adhami N, Frankos M, et al. Cigarette Smoke Toxins Deposited on Surfaces: Implications for Human Health. PLOS ONE. 2014;9(1):e86391. doi:10.1371/journal.pone.0086391.
  58. Stone WL, Bailey B, Khraisha N. The pathophysiology of smoking during pregnancy: a systems biology approach. Front Biosci Elite Ed. 2014;6:318-328.
  59. Ion R, Bernal AL. Smoking and Preterm Birth. Reprod Sci Thousand Oaks Calif. 2015;22(8):918-926. doi:10.1177/1933719114556486.
  60. Ekblad M, Korkeila J, Lehtonen L. Smoking during pregnancy affects foetal brain development. Acta Paediatr Oslo Nor 1992. 2015;104(1):12-18. doi:10.1111/apa.12791.
  61. Phelan S. Smoking cessation in pregnancy. Obstet Gynecol Clin North Am. 2014;41(2):255-266. doi:10.1016/j.ogc.2014.02.007.
  62. Hyland A, Piazza KM, Hovey KM, et al. Associations of lifetime active and passive smoking with spontaneous abortion, stillbirth and tubal ectopic pregnancy: a cross-sectional analysis of historical data from the Women’s Health Initiative. Tob Control. 2015;24(4):328-335. doi:10.1136/tobaccocontrol-2013-051458.
  63. Pineles BL, Park E, Samet JM. Systematic review and meta-analysis of miscarriage and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol. 2014;179(7):807-823. doi:10.1093/aje/kwt334.
  64. Chhabra D, Sharma S, Kho AT, et al. Fetal lung and placental methylation is associated with in utero nicotine exposure. Epigenetics. 2014;9(11):1473-1484. doi:10.4161/15592294.2014.971593.
  65. Fernandes M, Yang X, Li JY, Cheikh Ismail L. Smoking during pregnancy and vision difficulties in children: a systematic review. Acta Ophthalmol (Copenh). 2015;93(3):213-223. doi:10.1111/aos.12627.
  66. Curtin SC, Matthews TJ. Smoking Prevalence and Cessation Before and During Pregnancy: Data From the Birth Certificate, 2014. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst. 2016;65(1):1-14.
  67. Walker JF, Loprinzi PD. Longitudinal examination of predictors of smoking cessation in a national sample of U.S. adolescent and young adult smokers. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2014;16(6):820-827. doi:10.1093/ntr/ntu005.
  68. Park-Lee E, Ren C, Cooper M, Cornelius M, Jamal A, Cullen KA. Accessed April 29, 2022.
  69. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2008;10(12):1691-1715. doi:10.1080/14622200802443569.
  70. Heffner JL, Strawn JR, DelBello MP, Strakowski SM, Anthenelli RM. The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar Disord. 2011;13(5-6):439-453. doi:10.1111/j.1399-5618.2011.00943.x.
  71. Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged ≥18 years with mental illness - United States, 2009-2011. MMWR Morb Mortal Wkly Rep. 2013;62(5):81-87.
  72. Aubin H-J, Rollema H, Svensson TH, Winterer G. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev. 2012;36(1):271-284. doi:10.1016/j.neubiorev.2011.06.007.
  73. Minichino A, Bersani FS, Calò WK, et al. Smoking behaviour and mental health disorders—mutual influences and implications for therapy. Int J Environ Res Public Health. 2013;10(10):4790-4811. doi:10.3390/ijerph10104790.
  74. Wing VC, Wass CE, Soh DW, George TP. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci. 2012;1248:89-106. doi:10.1111/j.1749-6632.2011.06261.x.
  75. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014;348:g1151.
  76. Goodwin RD, Sheffer CE, Chartrand H, et al. Drug use, abuse, and dependence and the persistence of nicotine dependence. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2014;16(12):1606-1612. doi:10.1093/ntr/ntu115.
  77. Guydish J, Passalacqua E, Tajima B, Chan M, Chun J, Bostrom A. Smoking prevalence in addiction treatment: a review. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2011;13(6):401-411. doi:10.1093/ntr/ntr048.
  78. Center for Behavioral Health Statistics and Quality. Smoking and Mental Illness. Rockville (MD): SAMHSA; 2013. Accessed September 14, 2017.
  79. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry.2004; 61(11):1107–1115.
  80. Moran LV, Sampath H, Kochunov P, Hong LE. Brain circuits that link schizophrenia to high risk of cigarette smoking. Schizophr Bull. 2013;39(6):1373-1381. doi:10.1093/schbul/sbs149.
  81. Álvarez Gutiérrez FJ, Ferrer Galván M, Ruiz Bernal A, et al. Predictors of 10-year smoking abstinence in smokers abstinent for 1 year after treatment. Addict Abingdon Engl. 2016;111(3):545-551. doi:10.1111/add.13220.
  82. Tulloch HE, Pipe AL, Clyde MJ, Reid RD, Els C. The Quit Experience and Concerns of Smokers With Psychiatric Illness. Am J Prev Med. 2016;50(6):709-718. doi:10.1016/j.amepre.2015.11.006.
  83. Callaghan RC, Veldhuizen S, Jeysingh T, et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res. 2014;48(1):102-110. doi:10.1016/j.jpsychires.2013.09.014.
  84. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72(6):1144-1156. doi:10.1037/0022-006X.72.6.1144.
  85. Mackowick KM, Lynch M-J, Weinberger AH, George TP. Treatment of tobacco dependence in people with mental health and addictive disorders. Curr Psychiatry Rep. 2012;14(5):478-485. doi:10.1007/s11920-012-0299-2.
  86. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;(2):CD007253. doi:10.1002/14651858.CD007253.pub3.
  87. Stubbs B, Vancampfort D, Bobes J, De Hert M, Mitchell AJ. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatr Scand. 2015;132(2):122-130. doi:10.1111/acps.12412.
  88. Evins AE, Cather C, Laffer A. Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. Harv Rev Psychiatry. 2015;23(2):90-98. doi:10.1097/HRP.0000000000000063.
  89. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311(2):145-154. doi:10.1001/jama.2013.285113.
  90. Jain R, Majumder P, Gupta T. Pharmacological intervention of nicotine dependence. BioMed Res Int. 2013;2013:278392. doi:10.1155/2013/278392.
  91. West R, Raw M, McNeill A, et al. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addict Abingdon Engl. 2015;110(9):1388-1403. doi:10.1111/add.12998.
  92. Stead LF, Koilpillai P, Lancaster T. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2015;(10):CD009670. doi:10.1002/14651858.CD009670.pub3.
  93. Coleman T, Chamberlain C, Davey M-A, Cooper SE, Leonardi-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2012;(9):CD010078. doi:10.1002/14651858.CD010078.
  94. Aubin H-J, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol. 2014;77(2):324-336. doi:10.1111/bcp.12116.
  95. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329. doi:10.1002/14651858.CD009329.pub2.
  96. Prochaska JJ, Benowitz NL. The Past, Present, and Future of Nicotine Addiction Therapy. Annu Rev Med. 2016;67:467-486. doi:10.1146/annurev-med-111314-033712.
  97. Pbert L, Farber H, Horn K, et al. State-of-the-art office-based interventions to eliminate youth tobacco use: the past decade. Pediatrics. 2015;135(4):734-747. doi:10.1542/peds.2014-2037.
  98. Bailey SR, Crew EE, Riske EC, Ammerman S, Robinson TN, Killen JD. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. Paediatr Drugs. 2012;14(2):91-108. doi:10.2165/11594370-000000000-00000.
  99. Stanton A, Grimshaw G. Tobacco cessation interventions for young people. Cochrane Database Syst Rev. 2013;(8):CD003289. doi:10.1002/14651858.CD003289.pub5.
  100. Penberthy JK, Ait-Daoud N, Vaughan M, Fanning T. Review of treatment for cocaine dependence. Curr Drug Abuse Rev. 2010;3(1):49-62.
  101. Jhanjee S. Evidence based psychosocial interventions in substance use. Indian J Psychol Med. 2014;36(2):112-118. doi:10.4103/0253-7176.130960.
  102. Raja M, Saha S, Mohd S, Narang R, Reddy LVK, Kumari M. Cognitive Behavioural Therapy versus Basic Health Education for Tobacco Cessation among Tobacco Users: A Randomized Clinical Trail. J Clin Diagn Res JCDR. 2014;8(4):ZC47-ZC49. doi:10.7860/JCDR/2014/8015.4279.
  103. Webb MS, de Ybarra DR, Baker EA, Reis IM, Carey MP. Cognitive-behavioral therapy to promote smoking cessation among African American smokers: a randomized clinical trial. J Consult Clin Psychol. 2010;78(1):24-33. doi:10.1037/a0017669.
  104. Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015;(3):CD006936. doi:10.1002/14651858.CD006936.pub3.
  105. Witkiewitz K, Bowen S, Harrop EN, Douglas H, Enkema M, Sedgwick C. Mindfulness-based treatment to prevent addictive behavior relapse: theoretical models and hypothesized mechanisms of change. Subst Use Misuse. 2014;49(5):513-524. doi:10.3109/10826084.2014.891845.
  106. de Souza ICW, de Barros VV, Gomide HP, et al. Mindfulness-based interventions for the treatment of smoking: a systematic literature review. J Altern Complement Med N Y N. 2015;21(3):129-140. doi:10.1089/acm.2013.0471.
  107. Danielsson A-K, Eriksson A-K, Allebeck P. Technology-based support via telephone or web: a systematic review of the effects on smoking, alcohol use and gambling. Addict Behav. 2014;39(12):1846-1868. doi:10.1016/j.addbeh.2014.06.007.
  108. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013;(8):CD002850. doi:10.1002/14651858.CD002850.pub3.
  109. Mushtaq N, Boeckman LM, Beebe LA. Predictors of smokeless tobacco cessation among telephone quitline participants. Am J Prev Med. 2015;48(1 Suppl 1):S54-S60. doi:10.1016/j.amepre.2014.09.028.
  110. Chen Y-F, Madan J, Welton N, et al. Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis. Health Technol Assess Winch Engl. 2012;16(38):1-205, iii - v. doi:10.3310/hta16380.
  111. Hall AK, Cole-Lewis H, Bernhardt JM. Mobile text messaging for health: a systematic review of reviews. Annu Rev Public Health. 2015;36:393-415. doi:10.1146/annurev-publhealth-031914-122855.
  112. Keoleian V, Polcin D, Galloway GP. Text messaging for addiction: a review. J Psychoactive Drugs. 2015;47(2):158-176. doi:10.1080/02791072.2015.1009200.
  113. Nash CM, Vickerman KA, Kellogg ES, Zbikowski SM. Utilization of a Web-based vs integrated phone/Web cessation program among 140,000 tobacco users: an evaluation across 10 free state quitlines. J Med Internet Res. 2015;17(2):e36. doi:10.2196/jmir.3658.
  114. Civljak M, Stead LF, Hartmann-Boyce J, Sheikh A, Car J. Internet-based interventions for smoking cessation. Cochrane Database Syst Rev. 2013;(7):CD007078. doi:10.1002/14651858.CD007078.pub4.
  115. Elfeddali I, Bolman C, Candel MJJM, Wiers RW, de Vries H. Preventing smoking relapse via Web-based computer-tailored feedback: a randomized controlled trial. J Med Internet Res. 2012;14(4):e109. doi:10.2196/jmir.2057.
  116. Gulliver A, Farrer L, Chan JKY, et al. Technology-based interventions for tobacco and other drug use in university and college students: a systematic review and meta-analysis. Addict Sci Clin Pract. 2015;10:5. doi:10.1186/s13722-015-0027-4.
  117. Haines-Saah RJ, Kelly MT, Oliffe JL, Bottorff JL. Picture Me Smokefree: a qualitative study using social media and digital photography to engage young adults in tobacco reduction and cessation. J Med Internet Res. 2015;17(1):e27. doi:10.2196/jmir.4061.
  118. Ramo DE, Thrul J, Delucchi KL, Ling PM, Hall SM, Prochaska JJ. The Tobacco Status Project (TSP): Study protocol for a randomized controlled trial of a Facebook smoking cessation intervention for young adults. BMC Public Health. 2015;15:897. doi:10.1186/s12889-015-2217-0.
  119. Cressman AM, Pupco A, Kim E, Koren G, Bozzo P. Smoking cessation therapy during pregnancy. Can Fam Physician Med Fam Can. 2012;58(5):525-527.
  120. Leung LWS, Davies GA. Smoking Cessation Strategies in Pregnancy. J Obstet Gynecol Can JOGC. 2015;37(9):791-797. doi:10.1016/S1701-2163(15)30149-3.
  121. Tappin D, Bauld L, Purves D, et al. Financial incentives for smoking cessation in pregnancy: randomised controlled trial. BMJ. 2015;350:h134.
  122. Chamberlain C, O’Mara-Eves A, Oliver S, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2013;(10):CD001055. doi:10.1002/14651858.CD001055.pub4.
  123. Higgins ST, Washio Y, Heil SH, et al. Financial incentives for smoking cessation among pregnant and newly postpartum women. Prev Med. 2012;55 Suppl:S33-S40. doi:10.1016/j.ypmed.2011.12.016.
  124. Heil SH, Linares Scott T, Higgins ST. An overview of principles of effective treatment of substance use disorders and their potential application to pregnant cigarette smokers. Drug Alcohol Depend. 2009;104 Suppl 1:S106-S114. doi:10.1016/j.drugalcdep.2009.05.012.
  125. Nicotine Replacement Therapy for Smoking Cessation or Reduction: A Review of the Clinical Evidence. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014.
  126. Douaihy AB, Kelly TM, Sullivan C. Medications for substance use disorders. Soc Work Public Health. 2013;28(3-4):264-278. doi:10.1080/19371918.2013.759031.
  127. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;(1):CD000031. doi:10.1002/14651858.CD000031.pub4.
  128. Kaduri P, Voci S, Zawertailo L, Chaiton M, McKenzie K, Selby P. Real-world effectiveness of varenicline versus nicotine replacement therapy in patients with and without psychiatric disorders. J Addict Med. 2015;9(3):169-176. doi:10.1097/ADM.0000000000000111.
  129. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44(6):588-597. doi:10.3109/07853890.2012.705016.
  130. Pascual FP, Fontoba Ferrándiz J, Gil Sanchez MC, Ponce Lorenzo F, Botella Estrella C. Two-Year Therapeutic Effectiveness of Varenicline for Smoking Cessation in a Real World Setting. Subst Use Misuse. 2016;51(2):131-140. doi:10.3109/10826084.2015.1018547.
  131. Chang P-H, Chiang C-H, Ho W-C, Wu P-Z, Tsai J-S, Guo F-R. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015;15:689. doi:10.1186/s12889-015-2055-0.
  132. Tanner J-A, Chenoweth MJ, Tyndale RF. Pharmacogenetics of nicotine and associated smoking behaviors. Curr Top Behav Neurosci. 2015;23:37-86. doi:10.1007/978-3-319-13665-3_3.
  133. Lerman C, Schnoll RA, Hawk LW, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2):131-138. doi:10.1016/S2213-2600(14)70294-2.
  134. Lerman C, Gu H, Loughead J, Ruparel K, Yang Y, Stein EA. Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function. JAMA Psychiatry. 2014;71(5):523-530. doi:10.1001/jamapsychiatry.2013.4091.
  135. Harmey D, Griffin PR, Kenny PJ. Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2012;14(11):1300-1318. doi:10.1093/ntr/nts201.
  136. Alasmari F, Al-Rejaie SS, AlSharari SD, Sari Y. Targeting glutamate homeostasis for potential treatment of nicotine dependence. Brain Res Bull. 2016;121:1-8. doi:10.1016/j.brainresbull.2015.11.010.
  137. Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs. 2014;19(2):243-260. doi:10.1517/14728214.2014.899580.
  138. Turner JR, Gold A, Schnoll R, Blendy JA. Translational research in nicotine dependence. Cold Spring Harb Perspect Med. 2013;3(3):a012153. doi:10.1101/cshperspect.a012153.
  139. McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014;28(2):95-106. doi:10.1007/s40263-014-0142-x.
  140. Esterlis I, Hannestad JO, Perkins E, et al. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry. 2013;170(4):399-407. doi:10.1176/appi.ajp.2012.12060793.
  141. Goniewicz ML, Delijewski M. Nicotine vaccines to treat tobacco dependence. Hum Vaccines Immunother. 2013;9(1):13-25. doi:10.4161/hv.22060.
  142. Bellamoli E, Manganotti P, Schwartz RP, Rimondo C, Gomma M, Serpelloni G. rTMS in the treatment of drug addiction: an update about human studies. Behav Neurol. 2014;2014:815215. doi:10.1155/2014/815215.
  143. Sousa AD. Repetitive Transcranial Magnetic Stimulation (rTMS) in the Management of Alcohol Dependence and other Substance Abuse Disorders - Emerging Data and Clinical Relevance. Basic Clin Neurosci. 2013;4(3):271-275.
  144. Dinur-Klein L, Dannon P, Hadar A, et al. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. 2014;76(9):742-749. doi:10.1016/j.biopsych.2014.05.020.
  145. Chaloupka FJ, Yurekli A, Fong GT. Tobacco taxes as a tobacco control strategy. Tob Control. 2012;21(2):172-180. doi:10.1136/tobaccocontrol-2011-050417.
  146. Warner KE. Tobacco control policies and their impacts. Past, present, and future. Ann Am Thorac Soc. 2014;11(2):227-230. doi:10.1513/AnnalsATS.201307-244PS.
  147. Adachi-Mejia AM, Carlos HA, Berke EM, Tanski SE, Sargent JD. A comparison of individual versus community influences on youth smoking behaviours: a cross-sectional observational study. BMJ Open. 2012;2(5). doi:10.1136/bmjopen-2011-000767.
  148. Oesterle S, Hawkins JD, Kuklinski MR, et al. Effects of Communities That Care on Males’ and Females’ Drug Use and Delinquency 9 Years After Baseline in a Community-Randomized Trial. Am J Community Psychol. 2015;56(3-4):217-228. doi:10.1007/s10464-015-9749-4.
  149. Berrettini WH, Doyle GA. The CHRNA5-A3-B4 gene cluster in nicotine addiction. Mol Psychiatry. 2012;17(9):856-866. doi:10.1038/mp.2011.122.
  150. Agrawal A, Verweij KJH, Gillespie NA, et al. The genetics of addiction-a translational perspective. Transl Psychiatry. 2012;2:e140. doi:10.1038/tp.2012.54.
  151. Wang J-C, Kapoor M, Goate AM. The genetics of substance dependence. Annu Rev Genomics Hum Genet. 2012;13:241-261. doi:10.1146/annurev-genom-090711-163844.
  152. Chen L-S, Baker TB, Jorenby D, et al. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 2015;154:278-282. doi:10.1016/j.drugalcdep.2015.06.022.
  153. Bloom AJ, Murphy SE, Martinez M, von Weymarn LB, Bierut LJ, Goate A. Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption. Pharmacogenet Genomics. 2013;23(2):62-68. doi:10.1097/FPC.0b013e32835c3b48.
  154. Uhl GR, Walther D, Musci R, et al. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Mol Psychiatry. 2014;19(1):50-54. doi:10.1038/mp.2012.155.
  155. King DP, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012;37(3):641-650. doi:10.1038/npp.2011.232.
  156. Tsaprouni LG, Yang T-P, Bell J, et al. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics. 2014;9(10):1382-1396. doi:10.4161/15592294.2014.969637.
  157. Ladd-Acosta C, Shu C, Lee BK, et al. Presence of an epigenetic signature of prenatal cigarette smoke exposure in childhood. Environ Res. 2016;144(Pt A):139-148. doi:10.1016/j.envres.2015.11.014.
  158. Joubert BR, Felix JF, Yousefi P, et al. DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-analysis. Am J Hum Genet. 2016;98(4):680-696. doi:10.1016/j.ajhg.2016.02.019.
  159. Moran-Santa Maria MM, Hartwell KJ, Hanlon CA, et al. Right anterior insula connectivity is important for cue-induced craving in nicotine-dependent smokers. Addict Biol. 2015;20(2):407-414. doi:10.1111/adb.12124.
  160. Sutherland MT, McHugh MJ, Pariyadath V, Stein EA. Resting state functional connectivity in addiction: Lessons learned and a road ahead. NeuroImage. 2012;62(4):2281-2295. doi:10.1016/j.neuroimage.2012.01.117.
  161. Weiland BJ, Sabbineni A, Calhoun VD, Welsh RC, Hutchison KE. Reduced executive and default network functional connectivity in cigarette smokers. Hum Brain Mapp. 2015;36(3):872-882. doi:10.1002/hbm.22672.
  162. Menossi HS, Goudriaan AE, de Azevedo-Marques Périco C, et al. Neural bases of pharmacological treatment of nicotine dependence - insights from functional brain imaging: a systematic review. CNS Drugs. 2013;27(11):921-941. doi:10.1007/s40263-013-0092-8.
  163. Nees F, Witt SH, Lourdusamy A, et al. Genetic risk for nicotine dependence in the cholinergic system and activation of the brain reward system in healthy adolescents. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(11):2081-2089. doi:10.1038/npp.2013.131.
  164. Sweitzer MM, Donny EC, Hariri AR. Imaging genetics and the neurobiological basis of individual differences in vulnerability to addiction. Drug Alcohol Depend. 2012;123 Suppl 1:S59-S71. doi:10.1016/j.drugalcdep.2012.01.017.
  165. U.S. Food and Drug Administration. Retrieved from Accessed January 17, 2020.
  166. B Han, ND Volkow, C Blanco, D Tipperman, EB Einstein, WM Compton. Trends in prevalence of cigarette smoking among US adults with major depression or substance use disorders, 2006-2019JAMA. DOI: 10.1001/jama.2022.4790 (2022)